(Q36934785)

17 August 2017

1 reference

title

Therapeutic options for hormone-refractory prostate cancer in 2007. (English)

1 reference

17 August 2017

1 reference

Boris A Hadaschik

1

0 references

author name string

Martin E Gleave

series ordinal

2

1 reference

17 August 2017

1 September 2007

1 reference

17 August 2017

1 reference

17 August 2017

25

1 reference

17 August 2017

413-419

1 reference

17 August 2017

5

1 reference

17 August 2017

Cancer statistics, 2007

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.010

MANAGEMENT OF HORMONE REFRACTORY PROSTATE CANCER: CURRENT STANDARDS AND FUTURE PROSPECTS

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.010

Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.010

Mechanisms of the development of androgen independence in prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.010

Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.010

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.010

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.010

Post-therapy changes in PSA as an outcome measure in prostate cancer clinical trials.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.010

Angiogenic inhibitors: a new therapeutic strategy in oncology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.010

Tumorigenesis and the angiogenic switch

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.010

VEGF as a therapeutic target in cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.010

Association of preoperative plasma levels of vascular endothelial growth factor and soluble vascular cell adhesion molecule-1 with lymph node status and biochemical progression after radical prostatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.010

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.010

A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.010

Angiogenesis inhibition plus chemotherapy for metastatic hormone refractory prostate cancer: history and rationale

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.010

Properties of thalidomide and its analogues: implications for anticancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.010

Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.010

Thalidomide/estramustine/paclitaxel in metastatic androgen-independent prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.010

The endothelin axis: emerging role in cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.010

Targeting bone metastasis in prostate cancer with endothelin receptor antagonists

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.010

Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.010

Combination docetaxel and platelet-derived growth factor receptor inhibition with imatinib mesylate in prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.010

Targeting platelet-derived growth factor receptor on endothelial cells of multidrug-resistant prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.010

A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.010

Is there a role for platinum chemotherapy in the treatment of patients with hormone-refractory prostate cancer?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.010

Satraplatin: an orally available platinum analog for the treatment of cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.010

Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.010

Epothilones and the next generation of phase III trials for prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.010

Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.010

Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.010

Epothilones: mechanism of action and biologic activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.010

Antisense therapy for cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.010

Phase III study of gemcitabine and cisplatin with or without aprinocarsen, a protein kinase C-alpha antisense oligonucleotide, in patients with advanced-stage non-small-cell lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.010

Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.010

Challenge and promise: roles for clusterin in pathogenesis, progression and therapy of cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.010

Clusterin is a secreted mammalian chaperone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.010

Expression of clusterin in prostate cancer correlates with Gleason score but not with prognosis in patients undergoing radical prostatectomy without neoadjuvant hormonal therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.010

Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.010

Silencing expression of the clusterin/apolipoprotein j gene in human cancer cells using small interfering RNA induces spontaneous apoptosis, reduced growth ability, and cell sensitization to genotoxic and oxidative stress

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.010

A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.010

A phase I study of antisense oligonucleotide GTI-2040 given by continuous intravenous infusion in patients with advanced solid tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.010

Hormone therapy failure in human prostate cancer: analysis by complementary DNA and tissue microarrays.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.010

Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.010

On the role of Hsp27 in regulating apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.010

Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.010

10.1016/J.UROLONC.2007.05.010

7 January 2021

Identifiers

DOI

1 reference

17 August 2017

1 reference

PubMed ID

17826663